Annals of Surgical Oncology Sign the Guestbook
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Miliotes, G.
Right arrow Articles by Reintgen, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Miliotes, G.
Right arrow Articles by Reintgen, D.

Annals of Surgical Oncology, Vol 3, Issue 6 558-563, Copyright © 1996 by Society of Surgical Oncology

ARTICLES

Evaluation of new putative tumor markers for melanoma

G. Miliotes, G. H. Lyman, C. W. Cruse, C. Puleo, P. A. Albertini, D. Rapaport, F. Glass, N. Fenske, T. Soriano, C. Cuny, N. Van Voorhis and D. Reintgen
Division of Medical Oncology, Moffitt Cancer Center and Research Institute, University of South Florida, Tampa 33612-9497, USA.

BACKGROUND: The early diagnosis of recurrent melanoma can contribute to better outcome if the disease can be surgically resected or if the metastases are responsive to systemic therapies. Lipid-associated sialic acid (LASA-P) and the S-100 protein (S-100) were evaluated as tumor markers for melanoma with the goal of early detection of recurrence. METHODS: Sixty-seven patients were identified who had levels of S-100 and LASA-P drawn during their clinical course. A multivariate regression analysis was performed to determine the significance of the serum markers in relation to other prognostic factors for melanoma. RESULTS: After a median follow-up of 30 months, 58 patients had recurrences, and 49 patients died of disease. LASA-P elevation was not associated with the time to recurrence (p = 0.2176) or survival (p = 0.2507). S-100 positivity was a significant predictor of recurrence (p < 0.0001) and survival (p = 0.0059). The median time to recurrence for S-100-positive and S-100-negative patients was 7.6 and 33.8 months, respectively. The median survival time was 59.2 months for S-100-negative patients and 29.6 months for patients positive for S-100. CONCLUSIONS: Serum S-100 shows significant correlations to both time to recurrence and survival and could be useful in the clinical detection of malignant melanoma.


This article has been cited by other articles:


Home page
 Ann. Surg. Oncol.Home page
D. Ribuffo, A. Gradilone, M. Vonella, S. Chiummariello, E. Cigna, N. Haliassos, R. Massa, I. Silvestri, S. Calvieri, L. Frati, et al.
Prognostic Significance of Reverse Transcriptase-Polymerase Chain Reaction-Negative Sentinel Nodes in Malignant Melanoma
Ann. Surg. Oncol., May 1, 2003; 10(4): 396 - 402.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
M. H. Chung, R. K. Gupta, R. Essner, W. Ye, R. Yee, and D. L. Morton
Serum TA90 Immune Complex Assay Can Predict Outcome After Resection of Thick (>=4 mm) Primary Melanoma and Sentinel Lymphadenectomy
Ann. Surg. Oncol., March 1, 2002; 9(2): 120 - 126.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. C. Kelley, R. K. Gupta, E. C. Hsueh, R. Yee, S. Stern, and D. L. Morton
Tumor-Associated Antigen TA90 Immune Complex Assay Predicts Recurrence and Survival After Surgical Treatment of Stage I-III Melanoma
J. Clin. Oncol., February 15, 2001; 19(4): 1176 - 1182.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. D. Martenson, L.O. Hansson, B. Nilsson, E. von Schoultz, E. M. Brahme, U. Ringborg, and J. Hansson
Serum S-100B Protein as a Prognostic Marker in Malignant Cutaneous Melanoma
J. Clin. Oncol., February 1, 2001; 19(3): 824 - 831.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1996 by the Society of Surgical Oncology.